Skip to main content
Top

25-09-2024 | Cushing's Syndrome | Original Article

Impact of cortisol on liver fat and metabolic health in adrenal incidentalomas and Cushing’s syndrome

Authors: Peng Yu, Haoyue Yuan, Xiaomu Li, Hong Chen

Published in: Endocrine

Login to get access

Abstract

Objective

To evaluate liver fat content in patients with non-functional adrenal incidentalomas (NFAI), mild autonomous cortisol secretion (MACS), and Cushing’s syndrome (CS), and assess its relationship with cortisol levels.

Methods

This cross-sectional study used retrospective data from 103 NFAI patients, 100 MACS (serum cortisol after a 1-mg dexamethasone test >50 nmol/L), and 59 with CS. Abdominal CT scans measured hepatic and splenic CT values to calculate the liver-to-spleen (L/S) ratio. Metabolic indicators including fasting plasma glucose (FPG), LDL-c, HDL-c, HbA1c, etc were measured. Mediation analysis was used to explore the indirect effects of metabolic traits on the cortisol-liver fat relationship.

Results

Patients included 103 NFAI, 100 MACS, and 59 CS. MACS patients had higher NAFLD prevalence (57%) than NFAI (26.2%, p < 0.001) but lower than CS (66.1%, p < 0.001). MACS and CS were associated with NAFLD (OR 3.83 and OR 5.73, p < 0.01), adjusted for age, body mass index (BMI), and covariates. Midnight serum cortisol correlated with L/S ratio (p < 0.001). HbA1c and Triglyceride-glucose index (TyG) mediated 24.5% and 49.5% of the cortisol and L/S ratio association, respectively. FPG, HbA1c, HDL-c, and TyG mediated the association between MACS or CS and the L/S ratio. Homeostasis model assessment of insulin resistance (HOMA-IR), fructosamine, and triglycerides mediated for MACS, while alkaline phosphatase did so for CS. Total cholesterol, LDL-c, ALT, AST, γ-GT, insulin, and uric acid did not mediate the association.

Conclusion

MACS and CS are linked to significant metabolic disturbances, including increased liver fat and impaired glucose and lipid metabolism, contributing to fatty liver.
Literature
1.
go back to reference G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, A.J. McCullough, S. Natale, G. Forlani, N. Melchionda, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8), 1844–1850 (2001)CrossRefPubMed G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, A.J. McCullough, S. Natale, G. Forlani, N. Melchionda, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8), 1844–1850 (2001)CrossRefPubMed
2.
go back to reference E. Muzurović, D.P. Mikhailidis, C. Mantzoros, Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 119, 154770 (2021)CrossRefPubMed E. Muzurović, D.P. Mikhailidis, C. Mantzoros, Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 119, 154770 (2021)CrossRefPubMed
3.
go back to reference G. Targher, C.P. Day, E. Bonora, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363(14), 1341–1350 (2010)CrossRefPubMed G. Targher, C.P. Day, E. Bonora, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363(14), 1341–1350 (2010)CrossRefPubMed
4.
go back to reference S.A. Harrison, P. Bedossa, C.D. Guy, J.M. Schattenberg, R. Loomba, R. Taub, D. Labriola, S.E. Moussa, G.W. Neff, M.E. Rinella et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390(6), 497–509 (2024)CrossRefPubMed S.A. Harrison, P. Bedossa, C.D. Guy, J.M. Schattenberg, R. Loomba, R. Taub, D. Labriola, S.E. Moussa, G.W. Neff, M.E. Rinella et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390(6), 497–509 (2024)CrossRefPubMed
5.
go back to reference G. Targher, A.P. Rossi, G.A. Zamboni, F. Fantin, A. Antonioli, F. Corzato, C. Bambace, R. Pozzi Mucelli, M. Zamboni, Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J. Endocrinol. Invest. 35(8), 748–753 (2012)PubMed G. Targher, A.P. Rossi, G.A. Zamboni, F. Fantin, A. Antonioli, F. Corzato, C. Bambace, R. Pozzi Mucelli, M. Zamboni, Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J. Endocrinol. Invest. 35(8), 748–753 (2012)PubMed
6.
go back to reference J. Ko, I.R. Sequeira, L. Skudder-Hill, J. Cho, S.D. Poppitt, M.S. Petrov, Metabolic traits affecting the relationship between liver fat and intrapancreatic fat: a mediation analysis. Diabetologia 66(1), 190–200 (2023)CrossRefPubMed J. Ko, I.R. Sequeira, L. Skudder-Hill, J. Cho, S.D. Poppitt, M.S. Petrov, Metabolic traits affecting the relationship between liver fat and intrapancreatic fat: a mediation analysis. Diabetologia 66(1), 190–200 (2023)CrossRefPubMed
7.
go back to reference M. Zhang, Z. Shi, C. Wu, F. Yang, T. Su, X. Jing, J. Shi, H. Ren, L. Jiang, Y. Jiang et al. Cushing syndrome is associated with gut microbial dysbiosis and cortisol-degrading bacteria. J. Clin. Endocrinol. Metab. 109(6), 1474–1484 (2024)CrossRefPubMed M. Zhang, Z. Shi, C. Wu, F. Yang, T. Su, X. Jing, J. Shi, H. Ren, L. Jiang, Y. Jiang et al. Cushing syndrome is associated with gut microbial dysbiosis and cortisol-degrading bacteria. J. Clin. Endocrinol. Metab. 109(6), 1474–1484 (2024)CrossRefPubMed
8.
go back to reference V. Favero, C. Eller-Vainicher, V. Morelli, E. Cairoli, A.S. Salcuni, A. Scillitani, S. Corbetta, S.D. Casa, G. Muscogiuri, L. Persani et al. Increased risk of vertebral fractures in patients with mild autonomous cortisol secretion. J. Clin. Endocrinol. Metab. 109(2), e623–e632 (2024)CrossRefPubMed V. Favero, C. Eller-Vainicher, V. Morelli, E. Cairoli, A.S. Salcuni, A. Scillitani, S. Corbetta, S.D. Casa, G. Muscogiuri, L. Persani et al. Increased risk of vertebral fractures in patients with mild autonomous cortisol secretion. J. Clin. Endocrinol. Metab. 109(2), e623–e632 (2024)CrossRefPubMed
9.
go back to reference A.X. Chen, A. Radhakutty, S.M. Drake, A. Kiu, C.H. Thompson, M.G. Burt, Cardiovascular risk markers in adults with adrenal incidentaloma and mild autonomous cortisol secretion. J. Clin. Endocrinol. Metab. 109(3), e1020–e1028 (2024)CrossRefPubMed A.X. Chen, A. Radhakutty, S.M. Drake, A. Kiu, C.H. Thompson, M.G. Burt, Cardiovascular risk markers in adults with adrenal incidentaloma and mild autonomous cortisol secretion. J. Clin. Endocrinol. Metab. 109(3), e1020–e1028 (2024)CrossRefPubMed
10.
go back to reference M.K. Auer, G.K. Stalla, M.R. Stieg, Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. Pituitary 19(5), 461–471 (2016)CrossRefPubMedPubMedCentral M.K. Auer, G.K. Stalla, M.R. Stieg, Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. Pituitary 19(5), 461–471 (2016)CrossRefPubMedPubMedCentral
11.
go back to reference R. Pasquali, F. Casanueva, M. Haluzik, L. van Hulsteijn, S. Ledoux, M.P. Monteiro, J. Salvador, F. Santini, H. Toplak, O.M. Dekkers, European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur. J. Endocrinol. 182(1), G1–G32 (2020)CrossRefPubMed R. Pasquali, F. Casanueva, M. Haluzik, L. van Hulsteijn, S. Ledoux, M.P. Monteiro, J. Salvador, F. Santini, H. Toplak, O.M. Dekkers, European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur. J. Endocrinol. 182(1), G1–G32 (2020)CrossRefPubMed
12.
go back to reference V. Favero, A. Cremaschi, A. Falchetti, A. Gaudio, L. Gennari, A. Scillitani, F. Vescini, V. Morelli, C. Aresta, I. Chiodini, Management and medical therapy of mild hypercortisolism. Int. J. Mol. Sci. 22(21), 11521 (2021)CrossRefPubMedPubMedCentral V. Favero, A. Cremaschi, A. Falchetti, A. Gaudio, L. Gennari, A. Scillitani, F. Vescini, V. Morelli, C. Aresta, I. Chiodini, Management and medical therapy of mild hypercortisolism. Int. J. Mol. Sci. 22(21), 11521 (2021)CrossRefPubMedPubMedCentral
13.
go back to reference M. Fassnacht, S. Tsagarakis, M. Terzolo, A. Tabarin, A. Sahdev, J. Newell-Price, I. Pelsma, L. Marina, K. Lorenz, I. Bancos et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 189(1), G1–G42 (2023)CrossRefPubMed M. Fassnacht, S. Tsagarakis, M. Terzolo, A. Tabarin, A. Sahdev, J. Newell-Price, I. Pelsma, L. Marina, K. Lorenz, I. Bancos et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 189(1), G1–G42 (2023)CrossRefPubMed
14.
go back to reference Q.M. Anstee, T.L. Berentzen, L.M. Nitze, M. Jara, A.B. Jensen, M.S. Kjær, K.K. Mangla, J.M. Tarp, K. Khunti, Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study. Lancet Reg. Health Eur. 36, 100780 (2024)CrossRefPubMed Q.M. Anstee, T.L. Berentzen, L.M. Nitze, M. Jara, A.B. Jensen, M.S. Kjær, K.K. Mangla, J.M. Tarp, K. Khunti, Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study. Lancet Reg. Health Eur. 36, 100780 (2024)CrossRefPubMed
15.
go back to reference American DAPP: 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care 47(1), S20–S42 (2024) American DAPP: 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care 47(1), S20–S42 (2024)
16.
go back to reference K.J. Preacher, A.F. Hayes, Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav. Res. Methods 40(3), 879–891 (2008)CrossRefPubMed K.J. Preacher, A.F. Hayes, Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav. Res. Methods 40(3), 879–891 (2008)CrossRefPubMed
17.
go back to reference J. Westerbacka, H. Yki-Jarvinen, S. Vehkavaara, A.M. Hakkinen, R. Andrew, D.J. Wake, J.R. Seckl, B.R. Walker, Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J. Clin. Endocrinol. Metab. 88(10), 4924–4931 (2003)CrossRefPubMed J. Westerbacka, H. Yki-Jarvinen, S. Vehkavaara, A.M. Hakkinen, R. Andrew, D.J. Wake, J.R. Seckl, B.R. Walker, Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J. Clin. Endocrinol. Metab. 88(10), 4924–4931 (2003)CrossRefPubMed
18.
go back to reference R.E. Goldstein, D.H. Wasserman, O.P. McGuinness, D.B. Lacy, A.D. Cherrington, N.N. Abumrad, Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. Am. J. Physiol. 264(1 Pt 1), E119 (1993)PubMed R.E. Goldstein, D.H. Wasserman, O.P. McGuinness, D.B. Lacy, A.D. Cherrington, N.N. Abumrad, Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. Am. J. Physiol. 264(1 Pt 1), E119 (1993)PubMed
19.
go back to reference R. Ortiz, B. Kluwe, J.B. Odei, J.B. Echouffo Tcheugui, M. Sims, R.R. Kalyani, A.G. Bertoni, S.H. Golden, J.J. Joseph, The association of morning serum cortisol with glucose metabolism and diabetes: the Jackson Heart Study. Psychoneuroendocrinology 103, 25–32 (2019)CrossRefPubMed R. Ortiz, B. Kluwe, J.B. Odei, J.B. Echouffo Tcheugui, M. Sims, R.R. Kalyani, A.G. Bertoni, S.H. Golden, J.J. Joseph, The association of morning serum cortisol with glucose metabolism and diabetes: the Jackson Heart Study. Psychoneuroendocrinology 103, 25–32 (2019)CrossRefPubMed
20.
go back to reference S. Dinneen, A. Alzaid, J. Miles, R. Rizza, Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDM. Am. J. Physiol. 268(4 Pt 1), E595–E603 (1995)PubMed S. Dinneen, A. Alzaid, J. Miles, R. Rizza, Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDM. Am. J. Physiol. 268(4 Pt 1), E595–E603 (1995)PubMed
21.
go back to reference M.E. Cornide Petronio, E. Bujaldon, M. Mendes Braz, C.G. Avalos De León, M.B. Jiménez Castro, A.I. Álvarez Mercado, J. Gracia Sancho, J. Rodés, C. Peralta, The impact of cortisol in steatotic and non-steatotic liver surgery. J. Cell Mol. Med. 21(10), 2344–2358 (2017)CrossRefPubMedPubMedCentral M.E. Cornide Petronio, E. Bujaldon, M. Mendes Braz, C.G. Avalos De León, M.B. Jiménez Castro, A.I. Álvarez Mercado, J. Gracia Sancho, J. Rodés, C. Peralta, The impact of cortisol in steatotic and non-steatotic liver surgery. J. Cell Mol. Med. 21(10), 2344–2358 (2017)CrossRefPubMedPubMedCentral
22.
go back to reference F. Ferraù, M. Korbonits, Metabolic comorbidities in Cushing’s syndrome*. Eur. J. Endocrinol. 173(4), M133–M157 (2015)CrossRefPubMed F. Ferraù, M. Korbonits, Metabolic comorbidities in Cushing’s syndrome*. Eur. J. Endocrinol. 173(4), M133–M157 (2015)CrossRefPubMed
23.
go back to reference X. Sun, M. Feng, L. Lu, Z. Zhao, X. Bao, K. Deng, Y. Yao, H. Zhu, R. Wang. Lipid abnormalities in patients with Cushing’s disease and its relationship with impaired glucose metabolism. Front. Endocrinol. 11, 600323 (2021) X. Sun, M. Feng, L. Lu, Z. Zhao, X. Bao, K. Deng, Y. Yao, H. Zhu, R. Wang. Lipid abnormalities in patients with Cushing’s disease and its relationship with impaired glucose metabolism. Front. Endocrinol. 11, 600323 (2021)
24.
go back to reference S.A. Polyzos, G. Targher, Role of glucocorticoids in metabolic dysfunction-associated steatotic liver disease. Curr. Obes. Rep. 13(2), 242–255 (2024)CrossRefPubMedPubMedCentral S.A. Polyzos, G. Targher, Role of glucocorticoids in metabolic dysfunction-associated steatotic liver disease. Curr. Obes. Rep. 13(2), 242–255 (2024)CrossRefPubMedPubMedCentral
25.
go back to reference Y. Liang, M.C. Osborne, B.P. Monia, S. Bhanot, L.M. Watts, P. She, S.O. DeCarlo, X. Chen, K. Demarest, Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism 54(7), 848–855 (2005)CrossRefPubMed Y. Liang, M.C. Osborne, B.P. Monia, S. Bhanot, L.M. Watts, P. She, S.O. DeCarlo, X. Chen, K. Demarest, Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism 54(7), 848–855 (2005)CrossRefPubMed
26.
go back to reference C. Beaupere, A. Liboz, B. Fève, B. Blondeau, G. Guillemain, Molecular mechanisms of glucocorticoid-induced insulin resistance. Int. J. Mol. Sci. 22(2), 623 (2021)CrossRefPubMedPubMedCentral C. Beaupere, A. Liboz, B. Fève, B. Blondeau, G. Guillemain, Molecular mechanisms of glucocorticoid-induced insulin resistance. Int. J. Mol. Sci. 22(2), 623 (2021)CrossRefPubMedPubMedCentral
27.
go back to reference B. Friedmann, J.E.H. Goodman, S. Weinhouse, Effects of glucose feeding, cortisol, and insulin on liver glycogen synthesis in the rat. Endocrinology 81(3), 486 (1967)CrossRefPubMed B. Friedmann, J.E.H. Goodman, S. Weinhouse, Effects of glucose feeding, cortisol, and insulin on liver glycogen synthesis in the rat. Endocrinology 81(3), 486 (1967)CrossRefPubMed
28.
go back to reference R.M. de Guia, Stress, glucocorticoid signaling pathway, and metabolic disorders. Diab. Metab. Syndr. Clin. Res. Rev. 14(5), 1273–1280 (2020) R.M. de Guia, Stress, glucocorticoid signaling pathway, and metabolic disorders. Diab. Metab. Syndr. Clin. Res. Rev. 14(5), 1273–1280 (2020)
29.
go back to reference M.O. Weickert, A.F.H. Pfeiffer, Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49(8), 1732–1741 (2006)CrossRefPubMed M.O. Weickert, A.F.H. Pfeiffer, Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49(8), 1732–1741 (2006)CrossRefPubMed
Metadata
Title
Impact of cortisol on liver fat and metabolic health in adrenal incidentalomas and Cushing’s syndrome
Authors
Peng Yu
Haoyue Yuan
Xiaomu Li
Hong Chen
Publication date
25-09-2024
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-04043-4

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more